Idorsia Ltd To Discuss Phase 3 Program -Corporate Call Transcript
Dear, ladies and gentlemen, welcome to the conference call of Idorsia. As ordered from this request, this conference will be recorded. (Operator Instructions)
May I now hand you over to Andrew Weiss, who will lead you through this conference. Please go ahead.
Thank you, Olie. Good morning, good afternoon, everyone, and welcome to today's Idorsia call on the launch of the Phase III trial for selatogrel and suspected AMI.
Before I jump, I hand over the microphone to our participants. I do need to remind everybody that we will be making forward-looking statements in this call.
So with me on the call today, Slide 3, please, are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; and our Head of Global Clinical Development, Guy Braunstein.
To make his introductory comments, I hand over to Jean-Paul. Thank you.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |